However, the present results indicate that abnormal SPTBN2 promoter hypomethylation may be a major genomic driver of increased SPTBN2 expression in PAAD, and blocking epigenetic level abnormal SPTBN2 expression may represent a potential therapeutic strategy to reverse the occurrence of PAAD. This evidence concerns the gene SPTBN2 and pancreatic adenocarcinoma.